Orum Therapeutics
Greg Dwyer has extensive experience in the pharmaceutical industry, with a focus on business development. Greg is currently serving as the VP, Head of Business Development at Orum Therapeutics, where they are responsible for licensing the company's discovery platforms and development programs. Prior to this, Greg held the position of Senior Director, Business Development at Magenta Therapeutics from 2018 to 2021. Greg also worked at ImmunoGen, Inc. as a Senior Director, Director, and Associate Director of Business Development from 2011 to 2017. Before that, they were a Consultant and Analyst at Decision Resources, where they specialized in immune and inflammatory diseases. Greg began their career at Bristol-Myers Squibb as an Assistant Research Scientist. Throughout their career, Greg has gained expertise in drug markets, epidemiology-based forecasting, and understanding regulatory and reimbursement processes.
Greg Dwyer obtained their Bachelor of Science degree in Chemistry from Boston College, where they attended from 1996 to 2000. Following this, they pursued a Master of Business Administration (MBA) degree with a focus on Operations, Finance, and Strategy at Boston College Carroll School of Management from 2003 to 2006. Prior to their college education, Greg attended Hackensack High School from 1992 to 1996, though details regarding a degree or field of study are unavailable for this period.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.